


Vascular Remodelling in Pancreas Transplantation




Prof Steve White
Consultant HPB/Transplant Surgeon
The Freeman Hospital Newcastle
President Elect EPITA

European Pancreas Transplants

Pancreas Transplants 12/16/2005 – 12/31/2015




SPK Pancreas Graft Function




SPK Kidney Graft Function

USA Primary DD Pancreas Transplants, 1/1/1966 -12/31/2015



PTA Pancreas Graft Function




Pancreas *Graft Function*

USA DD Pancreas Transplants, 1/1/2003 – 12/31/2012

	SPK (8,345)		PAK (1,869)		PTA (884)	
	Primary only	All TxS	Primary only	All TxS	Primary only	All TxS
1- Year	86.2%	88.0%	78.6%	84.0%	78.0%	83.2%
3-Year	79.7%	81.4%	66.8%	72.0%	61.6%	68.0%
5-Year	73.0%	77.5%	58.1%	62.3%	53.9%	58.9%


Anti-T-Cell Induction

USA DD Primary Pancreas Transplants 1/1/1988 – 12/31/2015




HLA A,B,DR Mismatching

USA Primary DD Pancreas Transplants 1/1/1988 – 12/31/2015





cPRA levels > 20%

USA DD Primary Pancreas Transplants 1/1/2004 – 12/31/2015




1-Yr Immunological Graft Loss

USA DD Primary Pancreas Transplants, 10/1/1988 – 12/31/2003



5-Year Immunologic Graft Loss


USA DD Primary TS Pancreas Transplants, 1/1/1980 – 12/31/2015



Causes of Pancreas Graft Failure

3 - <12 Month Posttransplant

USA Primary DD Pancreas Transplants 1/1/2010 – 12/31/2015




Pancreas Graft Failure Cause

Causes of Pancreas Graft Failure

≥ 1 - 5 Years Posttransplant


USA Primary DD Pancreas Transplants 1/1/2000 – 12/31/2015



Pancreas Graft Failure Cause

SPK Pancreas Graft Loss due to Chronic Rejection

USA DD TS Primary Pancreas Transplants, 1/1/1988 – 12/31/1999



CHRONIC REJECTION: THE NEXT MAJOR CHALLENGE FOR PANCREAS TRANSPLANT RECIPIENTS

ABHINAV HUMAR,¹ KHALID KHWAJA, THIAGARAJAN RAMCHARAN, MASSIMO ASOLATI, RAJA KANDASWAMY, RAINER W. G. GRUESSNER, DAVID E. R. SUTHERLAND, AND ANGELIKA C. GRUESSNER

Objective. With newer immunosuppressive agents, acute rejection and graft loss resulting from acute rejection have become less common for pancreas transplant recipients. As long-term graft survival rates have improved, an increasing number of grafts are being lost to chronic rejection (CR). We studied the

creased after all types of abdominal and thoracic transplants. A better understanding of donor and recipient risk factors, coupled with improvements in preservation and surgical techniques, also helped decrease the incidence of graft loss to technical complications.

As a result, an increasing number of pancreas grafts are

TABLE 1. Causes of graft loss

	SPK (%)	PAK (%)	PTA (%)	Total (%)
Still functioning	230 (71.6)	267 (68.6)	146 (71.6)	643 (70.3)
Technical failure	48 (15.0)	49 (12.6)	21 (10.3)	118 (12.9)
Chronic rejection	12 (3.7)	45 (11.6)	23 (11.3)	80 (8.8)
Acute rejection	1 (0.3)	7 (1.8)	6 (2.9)	14 (1.5)
Death with function	26 (8.1)	19 (4.9)	6 (2.9)	51 (5.6)
Primary nonfunction	2 (0.6)	1 (0.3)	1 (0.5)	4 (0.4)
Other/unknown	2 (0.6)	1 (0.3)	1 (0.5)	4 (0.4)
Total	321	389 (0.3)	204	914

PAK, pancreas after kidney transplant; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney transplant.

Risk Factors

September 27, 2003

HUMAR ET AL.

921

TABLE 2. Multivariate analysis of risk factors for CR after pancreas transplants

Risk factor		RR	P Value
Acute rejection	Yes (vs. no)	4.41	<0.0001
Transplant category	PTA or PAK (vs. SPK)	3.02	0.002
CMV infection	Yes (vs. no)	2.41	0.001
Retransplant	Yes (vs. no)	2.27	0.004
PRA >20	Yes (vs. no)	1.73	0.10
Recipient age (yr)	≤45 (vs. >45)	—	NS
Number of mismatches at A locus	1 or 2 (vs. 0)	—	NS
Number of mismatches at B locus	1 or 2 (vs. 0)	1.68	0.04
Number of mismatches at DR locus	1 or 2 (vs. 0)	—	NS
Immunosuppression	MMF (vs. other)	—	NS
Immunosuppression	Sirolimus (vs. other)	—	NS

CMV, cytomegalovirus; PAK, pancreas after kidney transplant; PTA, pancreas transplant alone; SPK, simultaneous pancreas-kidney transplant; PRA, panel-reactive antibody; CR, chronic rejection; NS, not significant; RR, relative risk.


Distinct Histologic Patterns of Acute, Prolonged, and Chronic Rejection in Vascularized Rat Pancreas Allografts

**BIRTE STEINIGER, MD, and
JÜRGEN KLEMPNAUER, MD**

*From the Centre of Anatomy and Department of Abdominal and
Transplantation Surgery, Medical School, Hannover, Federal
Republic of Germany*

In a model of pancreas whole organ transplantation in streptozotocin diabetic rats distinct histologic patterns of acute, prolonged and chronic rejection were defined by light microscopy. Allotransplantation between major

morphology. The impact of surgical techniques with preserved and suppressed exocrine secretion on graft histology was sequentially assessed in pancreas isograft recipients. MHC incompatibility was associated with acute rejection, non-MHC disparity with prolonged rejection and RT1.C mismatch with chronic rejection. (Am J Pathol 1986, 124:253-262)



Longitudinal Histopathologic Assessment of Rejection After Bladder-drained Canine Pancreas Allograft Transplantation

R. D. M. Allen,* J. M. Grierson,* H. Ekberg,†
W. J. Hawthorne,† P. Williamson,*
S. A. Deane,† J. R. Chapman,* G. J. Stewart,*
and J. M. Little†

From the Pancreas Transplant Research Group,
Department of Surgery,† University of Sydney
Hospital, Sydney, Australia

blems of graft pancreatitis and vascular thrombosis. Furthermore serum and urine markers of rejection either occur late or are unreliable and are prone to misinterpretation because of the reluctance of clinicians to perform




Figure 6. Summary of vascular changes, unmodified by immunosuppression, seen after canine pancreas allograft transplantation (R, rejection).

Morphologic features of chronic rejection in kidney and less commonly transplanted organs


Sibley RK. Morphologic features of chronic rejection in kidney and less commonly transplanted organs.

Clin Transplantation 1994; 8: 293–298. © Munksgaard, 1994

Abstract: Chronic rejection is characterized by morphological evidence of destruction of the transplanted organ. The injury to the organ is associated with collagenization of variable degree. The destruction and fibrosis of the organ is probably the result of 1) direct alloimmune cytotoxic (rejection) of the organ tissue, and 2) secondary to fibroproliferative endarteritis (i.e., a final morphological feature of chronic rejection), which is characterized by narrowing of the intimal space due to a cellular fibrosis

Richard K. Sibley

Department of Surgical Pathology, Stanford
University Medical Center, Stanford, California,
U.S.A.



Histological Grading of Chronic Pancreas Allograft Rejection/Graft Sclerosis

John C. Papadimitriou^{a,*}, Cinthia B. Drachenberg^a, David K. Klassen^b, Lillian Gaber^c, Lorraine C. Racusen^d, Ludek Voska^e, Charles B. Cangro^b, Emilio Ramos^b, Ravinder Wali^b, Matthew R. Weir^b and Stephen T. Bartlett^f

Departments of ^a Pathology, ^b Medicine and


^f Surgery, University of Maryland, School of Medicine, Baltimore MD, USA

^c Department of Pathology, University of Tennessee, Memphis TN, USA

^d Department of Pathology, Johns Hopkins University School of Medicine, Baltimore MD, USA

Introduction

Biopsy-proven chronic rejection (CR) is the largest single cause of late pancreas allograft loss (1–3). The clinical presentation of CR is nonspecific, with loss of glycemic control being the main feature. Hyperglycemia may develop progressively or may be unmasked by infection or other physiologic stresses (1). However, the clinical usefulness of this feature is limited since with the development of hyperglycemia due to chronic rejection, the beta cell function is in general already irretrievably lost (1). The diagnostic specificity of hyperglycemia is also



Grade	0- 54 mths
	1- 24 mths
	2- 9 mths
	3 – 1-2 mths

Figure2: Grade I – Mild chronic rejection/graft sclerosis. Expansion of fibrous septa (<30% of core surface). The lobules show peripheral erosion and fragmentation, but the central areas are intact.

ACUTE AND CHRONIC REJECTION OVER TIME IN A TYPICAL CASE OF GRAFT LOSS





Figure 6: Acute and chronic rejection grades in serial biopsies from a PTA recipient who lost graft function 34 months after transplantation. Repeated episodes of acute rejection (including late rejections) and several instances of acute rejection grade IV occurred over time. Chronic rejection/graft sclerosis was initially non-existent but gradually progressed, leading to loss of graft function.



Vanishing Pancreatic Grafts

Christopher Pivetti¹, In Chul Hong¹, Chang H. Yoo¹, Sun Lee¹, Kenny Kim¹, Gregory Emmanuel¹, Jason Kim¹, Romy Chung¹, Slawomir Niewiadomski², Paul Wolf³, and R. F. Gittes⁴

From the ¹San Diego Microsurgical Institute, ²Scripps Mercy Hospital, ³University of California San Diego Medical Center, ⁴Scripps Clinic.

Comparison of pancreaticoduodenal transplants (PDT) and duct-ligated pancreas transplant (DLPT) were performed using syngeneic and allogeneic studies in rats. Both DLPT and PDT allogeneic grafts showed mild rejection. DLPT groups showed disorganized pathology and acini replaced by fat. Eventually, massive fibrosis was seen in the Islets of Langerhans, as well as rejection cellular infiltrates. In both PDT groups, normal histology was observed in the same period. Thus the effect of duct occlusion is highly detrimental for the grafts.

Key Words: Pancreaticoduodenal transplants, duct-ligated pancreas transplants


MATERIALS AND METHODS

Lewis (LW) and Sprague Dawley (SD) rats, weighing 250g to 300g of mixed sex were employed for syngeneic and allogeneic studies, respectively. Though SD strains of rats were inbred at the San Diego Microsurgical Institute for over 15 generations, transplantation of solid organs (heart or pancreas) between SD strains still shows mild to moderate rejection phenomena. Grafts between inbred LW strains showed no rejection phenomena.

Vascular remodelling

- Physiological process triggered by a number of insults
- Differs from pathological stenotic disease
 - Rejection
 - donor specific antibodies
- Incidental observation of pancreatic graft vessel narrowing necessitated further investigation after a change in practice on post-op imaging

SPK Arterial Early/Late




Renal Arterial Late



Results

- 8 patients
- 12 month period
- Standard immunosuppression
 - Alemtuzmab Tacrolimus, MM
- Surgical technique-Systemic

Procedure



Characteristic	Statistic
Sex - M:F	7:1
Recipient age	Median 43 (32-55)
Donor age	28 (9-51)
CIT	9.8 (7.4-13.5)
Drainage – Enteric:Bladder	6:2

Aims/methods


- Examine changes in axial/coronal diameters of the arterial conduit, external iliac artery (EIA), internal iliac artery (IIA), superior mesenteric artery (SMA), splenic artery (SA) and renal arteries
- Retrospective CT analysis
 - Measurements were made by experienced radiologists

Imaging timescales

- In 2012 CT angiography became routine for pancreas transplants in the early (<5 days) and late (< 6 months) post-transplant period



Mean Δ luminal diameter (mm)



Median % Δ (range)	0	-50 (40-70.4)	-60 (50-86.7)	-70.8 (0-80)	-57.8 (50-80)	-30.7 (0-77.8)
P value	n/a	<0.01	0.012	<0.01	<0.01	<0.01

Morbidity

- Acute rejection (n=1)
 - Resolved with steroids
 - Arterial branch thrombosis (n=2)
 - Anticoagulated
- Collection (n=2)
- Pancreatitis (n=1)



Follow up


- All grafts functioning @ median follow up 15 months (range 10-21)
- All patients insulin independent
- 3 patients developed de novo DSA
- Occurs independently of DSA
- No CMV infections

Summary

- Luminal narrowing of large pancreatic allograft vessels
 - No corresponding changes in renal arteries
- No apparent impact on short term graft function/survival
- ? Aetiology

Physiological remodelling	Pathological disease
<ul style="list-style-type: none">• Compensatory due to reduced demand	<ul style="list-style-type: none">• Stenotic vasculopathy• Immunological/rejection related

Transplant vasculopathy



Clinical implications

- Risk of thrombosis
- Graft survival
- Therapeutic Modulation-anti-angiogenesis
 - - PDGF, BMP4, A20, uric acid

